Comprehensive anti-tumor immunity evaluation system for thoracic malignancies using peripheral blood mononuclear cell

Comprehensive anti-tumor immunity evaluation system for thoracic malignancies using peripheral blood mononuclear cell - Comprehensive anti-tumor immunity evaluation system for thoracic malignancies using peripheral blood mononuclear cell

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000042005

Enrollment

2000

Registered

2020-10-04

Start date

2020-10-05

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

thoracic malignancies

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients diagnosed with thoracic malignancies (including clinically diagnosed cases) 2. Patients receiving anti-cancer drug treatment or radiation therapy 3. Over 20 years old at the time of consent 4. Patients with written consent to this study

Exclusion criteria

Exclusion criteria: 1. Patients who do not agree to this study in writing 2. Patients judged by the physician to be inappropriate for participation in this study

Design outcomes

Primary

Measure	Time frame
results of PBMC analysis	—

Countries

Japan

Contacts

Public ContactOu Yamaguchi

Saitama Medical University International Medical Center respiratory medicine

ouyamagu@saitama-med.ac.jp042-984-4111

Outcome results